Skip to main content
BDPT
OTC Life Sciences

BIOADAPTIVES Reports Q1 Loss, Going Concern, Material Weakness, and Default on Senior Debt

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$0.011
Mkt Cap
$132.095K
52W Low
$0.008
52W High
$0.13
Market data snapshot near publication time

summarizeSummary

BioAdaptives, Inc. filed its Q1 2026 report, revealing a going concern, material weaknesses in internal controls, and a default on senior debt, alongside critically low cash and substantial potential dilution.


check_boxKey Events

  • Going Concern Warning Reiterated

    The company's financial statements were prepared on a going concern basis, with management expressing substantial doubt about its ability to continue operations due to accumulated deficits and the need for additional capital.

  • Material Weakness in Internal Controls

    Management concluded that internal controls over financial reporting were ineffective due to inadequate segregation of duties, ineffective risk assessment, and insufficient written policies and procedures.

  • Default on Senior Securities

    The company is currently in default on 12% debentures issued in 2018, which were due in 2020, and is working on an alternative resolution.

  • Critically Low Cash Position

    Cash on hand decreased to $73,606 as of March 31, 2026, down from $158,445 at year-end 2025, indicating insufficient liquidity for the next twelve months.


auto_awesomeAnalysis

This quarterly report confirms severe financial distress, including a going concern warning, material weaknesses in internal controls, and a default on senior debt. The company's cash position is critically low at $73,606, and it faces massive potential dilution from over 266 million common stock equivalents, significantly exceeding its 12 million outstanding common shares. While the net loss decreased and initial revenue was generated, these positives are overshadowed by the fundamental solvency and operational risks.

At the time of this filing, BDPT was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $132.1K. The 52-week trading range was $0.01 to $0.13. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed BDPT - Latest Insights

BDPT
May 15, 2026, 4:23 PM EDT
Source: Wiseek News
Importance Score:
7
BDPT
May 15, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
9
BDPT
Apr 14, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
9